Fawzy and co-authors, using the Spiromics cohort of COPD pateints, published an interesting propensity- score based study where the self-reported daily aspirin use resulted in lower rate of exacerbations, less symptoms and improved quality of life.
Comment
This observational study, with a retrospective approach, showed the beneficial effect of aspirin use in COPD but also raises the need for a future randomized trial. The main challenge is the biased effect of a possible cardiovascular disease.